PD-L1 is thought to be adaptively expressed by tumour cells in response to inflammatory cytokines (for example, interferon-γ (IFNγ)2), thereby directly inhibiting T-cell-mediated killing3, 4, 5. The gene discussed is IFNG; the disease is neoplasm.